JAMP PAROXETINE TABLETS

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

PAROXETINE (PAROXETINE HYDROCHLORIDE)

Inapatikana kutoka:

JAMP PHARMA CORPORATION

ATC kanuni:

N06AB05

INN (Jina la Kimataifa):

PAROXETINE

Kipimo:

30MG

Dawa fomu:

TABLET

Tungo:

PAROXETINE (PAROXETINE HYDROCHLORIDE) 30MG

Njia ya uendeshaji:

ORAL

Vitengo katika mfuko:

15G/50G

Dawa ya aina:

Prescription

Eneo la matibabu:

SELECTIVE-SEROTONIN REUPTAKE INHIBITORS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0123131001; AHFS:

Idhini hali ya:

APPROVED

Idhini ya tarehe:

2020-11-17

Tabia za bidhaa

_JAMP Paroxetine Tablets ( paroxetine hydrochloride) _
_Page 1 of 64_
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
JAMP PAROXETINE TABLETS
Paroxetine Tablets
Tablets, 10 mg, 20 mg and 30 mg paroxetine (as paroxetine
hydrochloride), Oral
USP
Selective Serotonin Reuptake Inhibitor
JAMP Pharma Corporation
1310, rue Nobel
Boucherville, Quebec
J4B 5H3, Canada
Date of Initial Authorization:
November 17, 2020
Date of Revision:
April 27, 2023
Submission Control Number: 269630
_JAMP Paroxetine Tablets ( paroxetine hydrochloride) _
_Page 2 of 64_
_ _
RECENT MAJOR LABEL CHANGES
SECTION
DATE
7 WARNINGS AND PRECAUTIONS, Cardiovascular
04/2023
7 WARNINGS AND PRECAUTIONS, Hematologic
09/2022
7 WARNINGS AND PRECAUTIONS, Immune
09/2022
7 WARNINGS AND PRECAUTIONS, Neurologic
09/2022
7 WARNINGS AND PRECAUTIONS, Psychiatric
09/2022
7 WARNINGS AND PRECAUTIONS, Reproductive Health:
Female and Male Potential
09/2022
7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women
09/2022
2 CONTRAINDICATIONS
09/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
..............................................................................................
2
TABLE OF CONTENTS
................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
5
1
INDICATIONS
................................................................................................................
5
1.1
Pediatrics
................................................................................................................
5
1.2
Geriatrics
................................................................................................................
5
2
CONTRAINDICATIONS
...................................................................................................
5
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
...